N/A N=37 Pelvic Floor Physical Therapy vs Standard Care in Transgender Women Undergoing Vaginoplasty for Gender Affirmation
Pelvic Floor Disorders
Primary: Patient Reported Ease of Dilation — 6.6; 7.4; 8.0 units on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=18 Feasibility of Remote Data Collection With a Point of Care Device to Measure HbA1c
Pregnant · Postpartum
Primary: Feasibility to Obtain HbA1c Through Remote Data Collection — 17; 16 Participants
Phase 1 N=164 BI 836845 in Estrogen Receptor Positive Metastatic Breast Cancer
Neoplasms
Primary: Progression-free Survival (PFS) - Phase II Part — 7.3; 5.6 Months — p=0.9057
N/A N=186 Technology and Family Thriving Study
Alzheimer Disease · Dementia · Caregiver Burnout
Primary: Quality of Life in Alzheimer's Disease (QOL-AD) - Changes From Baseline (Older Adult) — 3.04; 3.00; 2.85; 2.94 score on a scale
N/A N=25 EPIONE Guided Lung Evaluation
Lung Cancer
Primary: Feasibility of the Device — 26 Number of targets reached
N/A N=10 Synchronized Brain and Hand Stimulation After Stroke
Stroke · Upper Extremity Paresis
Primary: Percent Change in Box and Block Test — 20 percent change of number of blocks — p=.04
Phase 1 N=18 Dose-Escalated Hypofractionated Adaptive Radiotherapy for Head and Neck Cancer
Head and Neck Neoplasm
Primary: Incidence of Dose-Limiting Toxicities at 50 Gy With Concurrent Atezolizumab — 2; 0; 0; 0 Participants
N/A N=162 Diabetes Journey: An Adolescent Adherence Barriers Intervention
Type 1 Diabetes · Adherence, Patient
Primary: Barriers to Diabetes Adherence Questionnaire-Youth Report Stress/Burnout Subscale — 2.36; 2.31 score on a scale
N/A N=12 Does Walking Performance Improve When Veterans With Leg Amputations Are Given Visual Feedback?
Amputation
Primary: Affected Leg Peak Propulsive Horizontal Ground Reaction Force — 0.151; 0.145; 0.166; 0.150 proportion of body weight
Phase 3 N=496 Efficacy and Safety Study of Rimegepant for Migraine Prevention in Japanese Subjects (Japan Only)
Migraine
Primary: Mean Change From Baseline in Number of Migraine Days Per Month From Week 9 to 12 of the Double-Blind Treatment (DBT) Phase — -2.4; -1.4 Days/month — p=0.0021
Phase 2 N=24 Intranasal Cocaine and Temperature Regulation During Exercise
Hyperthermia · Cocaine Use · Exercise
Primary: Change in Core Temperature — 1.19; 1.09; 1.20; 0.89 Celsius
Phase 2 N=41 Reducing Hippocampal Hyperactivity and Improving Cognition in Schizophrenia
Schizophrenia
Primary: Neurocognitive Function — 73.68; 74.04; 3.36; 3.96 Total score
Phase 1 N=54 A Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of VIS954 in Healthy Adult Participants
Healthy Volunteers
Primary: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse Events (TESAEs) — 2; 1; 1; 1 Participants
N/A N=75 Urease Breath Test for Rapid Characterization of Pneumonia
Pneumonia, Bacterial
Primary: Adverse Events — 3; 0; 1; 0 Participants
N/A N=36 Autonomic Neuromodulation by Transcutaneous Nerve Stimulation in Acute Ischaemic Stroke.
Ischemic Stroke · Thrombotic Stroke · Autonomic Dysfunction
Primary: Blood Pressure Variability — 0.106; 0.107 coefficient of variation